BBOT

BBOT is a clinical-stage oncology company that reached the public market via the August 2025 Helix Acquisition Corp. II SPAC merger, and the 10-K is unusually candid about what you are buying: 'a limited operating history, have not completed any clinical trials, have no products approved for commercial sale, have never commercialized a product, and have not generated any revenue.' The revenue line is blank in every year of the provided history (FY2023–FY2025), so there is no fundamental business to value — only a pipeline (BBO-8520, BBO-10203, BBO-11818 across the ONKORAS-101, BREAKER-101 and KONQUER-101 trials) whose worth is entirely contingent on data that has not yet read out. When the entire investment case rests on unproven clinical outcomes, the risk is unknowable from the filing alone, which is the definition of 'not investable now' under a disciplined framework.

The one genuine strength is the balance sheet, which the SPAC cash injection transformed: cash jumped +1,111% to $374M, equity rose +330% to $411M, and liabilities/equity sits at just 0.09x — essentially debt-free. Against FY2025 operating cash burn of -$114M, that funds roughly 3 years, and the company explicitly flags it 'may require additional capital.' Note the burn is accelerating (R&D +65.8% to $121M), so real runway is likely shorter and dilution is a when-not-if risk — the filing itself lists 'our ability to raise financing' and Nasdaq listing maintenance as live concerns.